Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 96.5% in August

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the target of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,646,299 shares, an increase of 96.5% from the July 30th total of 837,868 shares. Approximately 7.6% of the company’s stock are sold short. Based on an average daily volume of 33,615,368 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Valion Bio, Inc. Common Stock

An institutional investor recently bought a new position in Valion Bio, Inc. Common Stock stock. Foster & Motley Inc. bought a new stake in Valion Bio, Inc. Common Stock (NASDAQ:VBIO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 53,728 shares of the company’s stock, valued at approximately $2,715,000. Foster & Motley Inc. owned about 1.29% of Valion Bio, Inc. Common Stock as of its most recent filing with the Securities and Exchange Commission. 4.25% of the stock is currently owned by hedge funds and other institutional investors.

Valion Bio, Inc. Common Stock Stock Performance

Shares of Valion Bio, Inc. Common Stock stock opened at $0.12 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Valion Bio, Inc. Common Stock has a 52 week low of $0.11 and a 52 week high of $3.21. The firm’s 50 day moving average is $0.35 and its two-hundred day moving average is $0.71. The firm has a market capitalization of $2.68 million, a P/E ratio of -0.02 and a beta of 1.85.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.17) earnings per share for the quarter, topping the consensus estimate of ($408.00) by $405.83.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Valion Bio, Inc. Common Stock currently has an average rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.